Why FebriDx Is Different
A Rapid, Clinically Validated Answer at the Point of Care
FebriDx is a rapid, instrument-free, fingerstick blood test that identifies host immune response, not pathogens — enabling accurate differentiation between bacterial and non-bacterial infections in minutes.
Dual-Biomarker
Intelligence
- Combines MxA (viral immune response) and CRP (inflammatory marker)
- Outperforms single-marker approaches
Clinically Proven
Accuracy
- ~99% negative predictive value for ruling out bacterial infection
- FDA 510(k) cleared
- Validated in large, multi-center U.S. trials
Designed for Real-
World Care
- Results in ~10 minutes
- No instrumentation
- Fingerstick sample
- Fits urgent care and workflows
From Fingerstick to Clinical Insight in Minutes
Proven diagnostic tools like FebriDx exist, but access and adoption remain major barriers. The FAR Institute closes that gap by accelerating awareness, funding, and deployment—ensuring effective diagnostics reach those who need them most.
1
Fingerstick blood sample
2
Dual biomarker detection (MxA + CRP)
3
Clear visual result
4
Confident treatment decision
5
Reduced unnecessary antibiotics
Built for Those Advancing Public Health
From frontline care providers to global health partners and philanthropic organizations, the FAR Institute works with those focused on measurable impact, sustainable access, and better health outcomes.
- Healthcare systems & urgent care networks
- Public health organizations
- Global health NGOs
- Philanthropic partners
- Policymakers & researchers
FebriDx is FDA 510(k) cleared and backed by clinical validation and peer-reviewed research supporting its accuracy and real-world effectiveness.
Help Scale Proven Diagnostics Where They’re Needed Most
Support the FAR Institute’s work to expand access to clinically validated diagnostics like FebriDx and reduce unnecessary antibiotic use through awareness, funding, and deployment.
- Become a Partner
- Support Deployment Programs
- Contact the FAR Institute
